Inhibitor Therapeutics (INTI) Other Non-Current Assets (2015 - 2021)
Inhibitor Therapeutics' (INTI) quarterly Other Non-Current Assets came in at $2439.0 in Q3 2021, down 92.31% YoY from $31731.0 in Q3 2020, and down 75.02% on a QoQ basis from $9762.0 in Q2 2021.
Inhibitor Therapeutics (INTI) Other Non-Current Assets (2015 - 2021) Analysis & Trends
Inhibitor Therapeutics (INTI) has 7 years of Other Non-Current Assets data on file, last reported at $2439.0 in Q3 2021.
- Quarterly Other Non-Current Assets fell 92.31% year-over-year to $2439.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $2439.0 (down 92.31% YoY) and the FY2020 annual result came in at $24408.0, down 54.55% from the prior year.
- Other Non-Current Assets slipped to $2439.0 in Q3 2021, from $9762.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $134253.0 in Q1 2017 to a low of $2439.0 in Q3 2021.
- A 5-year average of $68346.0 and a median of $68346.0 in 2019 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2017 — Other Non-Current Assets slipped 20.69% — and 2021, when it slumped 92.31%.
- Tracing INTI's Other Non-Current Assets over 5 years: stood at $112284.0 in 2017, then retreated by 26.09% to $82992.0 in 2018, then sank by 35.29% to $53700.0 in 2019, then slumped by 54.55% to $24408.0 in 2020, then slumped by 90.01% to $2439.0 in 2021.
- The last three Other Non-Current Assets figures came in at $2439.0 (Q3 2021), $9762.0 (Q2 2021), and $17085.0 (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 2,439.00 |
| Jun 30, 2021 | 9,762.00 |
| Mar 31, 2021 | 17,085.00 |
| Dec 31, 2020 | 24,408.00 |
| Sep 30, 2020 | 31,731.00 |
| Jun 30, 2020 | 39,054.00 |
| Mar 31, 2020 | 46,377.00 |
| Dec 31, 2019 | 53,700.00 |
| Sep 30, 2019 | 61,023.00 |
| Jun 30, 2019 | 68,346.00 |
| Mar 31, 2019 | 75,669.00 |
| Dec 31, 2018 | 82,992.00 |
| Sep 30, 2018 | 90,315.00 |
| Jun 30, 2018 | 97,638.00 |
| Mar 31, 2018 | 104,961.00 |
| Dec 31, 2017 | 112,284.00 |
| Sep 30, 2017 | 119,607.00 |
| Jun 30, 2017 | 126,930.00 |
| Mar 31, 2017 | 134,253.00 |
| Dec 31, 2016 | 141,576.00 |